Skip to main content
. Author manuscript; available in PMC: 2023 Oct 3.
Published in final edited form as: Clin Cancer Res. 2017 May 11;23(14):3566–3574. doi: 10.1158/1078-0432.CCR-16-2900

Table 3.

Adverse events possibly, probably or definitely attributable to intratumoral HSV1716 administration

Adverse Events Grade 1 Grade 2 Grade 3
Anemia 1
Leukopenia 1 1
Lymphopenia 1
Neutropenia 1 1
Chills 1
Fever 2
Bruising 2
Constipation 1 1
Nausea 1
Anxiety 1
Back pain 2 2
Headache 2 1
Chest pain 1 1
Pleurisy 1
Atelectasis 1
Pneumothorax 1 1
HHS Vulnerability Disclosure